Kratom Lab Method Validation: Can You Trust the Number on a COA?

Suggested page / content hub: Learning Center → Lab Testing & Product Quality
Suggested URL slug: /learn/kratom-lab-method-validation/
SEO title: Kratom Lab Method Validation: How to Evaluate COA Results
Suggested excerpt: A laboratory result is useful only when the method is fit for the analyte, product matrix, concentration range and decision being made. This guide explains the evidence behind trustworthy kratom test results.
Kiody position: Educational, adults 21+; Kiody does not sell concentrated 7-OH.

A precise number can still answer the wrong question

A Certificate of Analysis may show mitragynine to two decimal places, lead in parts per million or Salmonella as “not detected.” The formatting looks precise. That precision is not, by itself, proof that the result is accurate, representative of the lot or suitable for the decision a customer wants to make.

Every laboratory result depends on a chain of questions:

1. Was the correct sample collected from the correct lot?
2. Was the method designed for the correct analyte and product form?
3. Was the method shown to perform adequately in that matrix and concentration range?
4. Did the laboratory verify that it could run the method correctly?
5. Were the analytical batch’s blanks, controls, calibrators and other checks acceptable?
6. Are the units, reporting limits, basis and uncertainty appropriate for the specification or legal threshold?
7. Does the report accurately describe what was measured—and avoid claiming more?

Method validation addresses much of the third question. Method verification addresses the fourth. Routine quality control addresses the fifth. Sampling and lot traceability address the first. A credible quality program needs all of them.

This guide focuses on validation, verification, daily method control and measurement uncertainty. It complements—not replaces—Kiody’s separate guides to representative sampling, lot numbers, laboratory accreditation and reading a COA.

Method validation in plain language

Method validation is a documented demonstration that an analytical method performs well enough for a defined intended use.

The phrase “intended use” is essential. A method is not simply valid or invalid in the abstract. Its performance is connected to:

• the analyte or organism being measured;
• the product matrix;
• the concentration range;
• the sample-preparation procedure;
• the instrument and data-analysis process;
• whether the result is qualitative, quantitative or identity-based; and
• the decision the result will support.

A method developed to quantify mitragynine in botanical leaf powder may not automatically be suitable for a concentrated liquid, gummy, resin, tablet or biological specimen. A method validated around percent-level mitragynine may not have enough sensitivity or selectivity to quantify trace 7-hydroxymitragynine near a low regulatory threshold. A heavy-metal method validated for one food matrix may require additional evidence before it is used for a botanical powder with different digestion behavior or interferences.

FDA’s Foods Program describes formal processes for developing, validating and implementing analytical methods. Its chemical-method validation guidelines use performance levels tied to the intended regulatory purpose. The details are written for FDA laboratories, but the central lesson is valuable to every COA reader: validation is planned evidence, not a label placed on a method after one successful run.

As a quality-system benchmark, 21 CFR § 111.320 requires verification that laboratory methods are appropriate for their intended use and use of an appropriate scientifically valid method for each tested specification. Kiody should describe this as a benchmark for evaluating evidence, not as FDA recognition of kratom’s regulatory status.

Validation, verification and routine quality control are different

These terms are related but should not be used interchangeably.

Activity	Main question	Typical evidence
Method development	How should the measurement be performed?	Experiments selecting preparation, separation, detection and calculations
Method validation	Can the method perform adequately for its defined intended use?	Planned studies of selectivity, accuracy, precision, range, sensitivity, robustness and other characteristics
Method verification	Can this laboratory successfully perform an established method for the relevant matrix and use?	Laboratory-specific checks using standards, matrix samples, controls and predefined acceptance criteria
Method transfer	Can another location, instrument or team reproduce the method appropriately?	Comparative protocol, training, side-by-side samples and acceptance criteria
Routine quality control	Was this particular analytical batch under control?	Blanks, calibrators, spikes, reference materials, duplicates, continuing checks and control charts
Measurement uncertainty	How much dispersion is reasonably associated with the reported value?	Defined measurement model, identified components, calculations and supporting data

A method may have a strong published validation and still be performed poorly in a particular batch. Conversely, a batch with attractive control results does not repair a method that was never demonstrated to separate an analyte from an interfering compound.

The most useful question is not “Is the lab accredited?” or “Is the method validated?” in isolation. It is:

What current evidence shows that this laboratory, at this location, used an appropriate method under control for this analyte, matrix, range and lot?

The intended use comes before the acceptance criteria

A validation plan should define the measurement problem before collecting performance data.

For a kratom alkaloid method, that definition may include:

• Analytes: mitragynine, 7-hydroxymitragynine and any additional named alkaloids;
• Matrix: dried leaf, milled powder, pure-leaf capsule fill, finished capsule, liquid extract or another form;
• Basis: as-received weight, dry weight, product weight, serving, article or total-alkaloid fraction;
• Range: the lowest through highest concentration intended to be reported;
• Purpose: informational profile, internal specification, label claim or comparison with a legal product threshold;
• Reporting convention: numerical result, less-than value, not detected, present/absent or identity confirmation;
• Required sensitivity: reporting limit below the decision level; and
• Decision rule: how rounding and uncertainty are considered near a limit.

If these points are missing, the word “validated” has too little context. A method can perform very well inside one range and poorly outside it. A report may dilute a high sample into range, but dilution integrity must be supported. It may detect a trace signal below the level it can quantify reliably, but the report should not turn that signal into an unjustifiably precise number.

The core performance characteristics

There is no single universal validation checklist for every type of analysis. Chemistry, microbiology, DNA-based identity work and physical measurements have different needs. The following characteristics are common in quantitative chemical methods and illustrate the questions a technically serious review should ask.

1. Selectivity or specificity: is the method measuring the right thing?

Selectivity is the method’s ability to distinguish the target from other substances that may be present. In kratom work, this can be challenging because botanical material contains many structurally related alkaloids and other matrix components.

A peak at an expected time is not automatically proof of identity. Depending on the method and decision, evidence may involve:

• chromatographic separation;
• retention-time agreement;
• characteristic ions or ion ratios;
• exact-mass criteria;
• comparison with an authenticated reference standard;
• resolution of isomers or closely related compounds;
• analysis of blank matrix and potential interferences; and
• confirmation rules defined before samples are analyzed.

This matters especially for low-level 7-OH work. A 2026 primary research paper described analytical approaches intended to avoid false identification of 7-hydroxymitragynine in commercial-product testing. The broader lesson is not that one method is mandatory; it is that an unresolved interference or mistaken identity can create a confident-looking but incorrect result.

Selectivity also matters in heavy-metal and pesticide testing. Botanical matrices can suppress or enhance instrument response, introduce spectral interferences or affect extraction. The method must control or account for those effects.

2. Calibration model, linearity and working range

Quantitative methods compare sample response with known standards. The relationship may be linear, weighted linear or another justified model. A high correlation coefficient alone does not prove that the calibration is appropriate.

A useful validation examines:

• the number and placement of calibration levels;
• preparation and traceability of standards;
• whether the model fits across the claimed range;
• behavior of residuals;
• weighting, when used;
• back-calculated calibration accuracy;
• the lower and upper limits of quantitation;
• what happens above the upper limit; and
• whether dilution brings high samples into range without bias.

The calibration range should bracket expected sample results after documented preparation and dilution. A result obtained by extrapolating far outside the validated range should not be presented as equivalent to one measured inside it.

For customers, a practical question is: Was the reported value inside the method’s validated quantitative range? The full COA may not answer this, but a qualified laboratory should be able to explain its reporting range and dilution procedure.

3. Accuracy, trueness and recovery

These terms are sometimes used loosely. At a practical level, the laboratory needs evidence that the method’s result agrees adequately with an accepted reference or known addition.

Evidence may include:

• certified reference material;
• an independently characterized reference material;
• matrix material fortified with a known amount of analyte;
• comparison with a recognized reference method; or
• another justified approach when suitable material is unavailable.

Recovery asks how much of a known addition is found after the measurement process. A recovery study should mimic the parts of the process it is intended to evaluate. Adding a standard to the final vial can test instrument response but may not test extraction from leaf powder. Adding analyte before extraction can better challenge the preparation step, though it may still not perfectly reproduce analyte naturally bound or distributed in plant material.

FDA’s Elemental Analysis Manual explains that reference materials are used for validation, verification, calibration and quality control. The certificate and matrix matter. A reference material with a certified lead value does not automatically validate arsenic, cadmium, mercury or alkaloid measurements.

4. Precision: do repeated measurements agree closely enough?

Precision concerns the closeness of repeated results under defined conditions. Important levels include:

• Repeatability: same method, location, equipment, analyst or short time interval under closely controlled conditions;
• Intermediate precision: variation across days, analysts, instruments, columns, reagent lots or other normal within-laboratory changes; and
• Reproducibility: variation among laboratories, often evaluated through collaborative studies or comparisons.

Replicate instrument injections show only part of the picture. If the same prepared vial is injected repeatedly, the study may not capture variation from weighing, extraction, dilution or different portions of a nonuniform botanical powder.

A stronger precision study matches the intended workflow. If routine testing starts with separately weighed portions, validation should include independently prepared replicates. If multiple analysts and instruments will be used, intermediate-precision work should represent that reality.

Precision is commonly summarized using a standard deviation or relative standard deviation. A small number is meaningful only when the replicate design and concentration level are known.

5. Detection limit, quantitation limit and reporting limit

The limit of detection, or LOD, concerns the lowest level that can be reliably distinguished from the relevant background under the method. The limit of quantitation, or LOQ, concerns the lowest level that can be quantified with acceptable performance. The reporting limit is the level or convention the laboratory uses when issuing results; it may be at or above the method’s demonstrated capability.

These values are not interchangeable, and none means that a substance below the limit is proven absent.

For a limit comparison, sensitivity must be fit for purpose. If a legal or internal threshold is lower than the LOQ, the method may be unable to provide a reliable numerical determination at the decision point. A report of “ND” without the relevant detection or reporting limit does not show how sensitive the test was.

Low-level validation should include matrix-relevant evidence, not only instrument response from clean solvent. Matrix background and sample preparation can change practical detection and quantitation performance.

6. Robustness and ruggedness

Robustness studies evaluate whether small, deliberate changes produce unacceptable effects. Depending on the method, variables can include:

• extraction time;
• solvent composition;
• pH;
• column temperature;
• flow rate;
• instrument settings;
• different columns or reagent lots;
• incubation conditions; or
• sample-holding time.

The goal is not to prove that every change is harmless. It is to understand which variables must be tightly controlled and whether routine variation threatens the result.

For a botanical matrix, extraction conditions deserve special attention. An incomplete or unstable extraction can bias the result even when the instrument itself performs perfectly.

7. Carryover, stability and dilution integrity

High-concentration samples can leave residual analyte that appears in the next injection. Carryover checks help show whether blanks after high standards or samples remain acceptable.

Stability studies can address:

• prepared standard solutions;
• processed sample extracts;
• autosampler residence;
• storage temperature;
• freeze-thaw cycles when relevant; and
• light or oxidation sensitivity.

Dilution integrity evaluates whether a sample above the range can be diluted and measured accurately. This is particularly important when the same method handles ordinary botanical leaf and much more concentrated materials. A laboratory should not assume that an extreme dilution preserves accuracy without evidence.

Matrix effects: why “we tested a standard” is not enough

A matrix is everything in the submitted material other than the target being measured. Kratom leaf is a complex plant matrix containing pigments, fibers, minerals and numerous chemical constituents. Capsule shells, flavor systems, sweeteners, acids, oils and extract carriers can create different matrices.

Matrix components can:

• reduce or increase detector response;
• interfere with extraction;
• overlap with the target signal;
• contaminate equipment;
• alter digestion or recovery;
• affect microbial detection; or
• push a sample outside the method’s assumptions.

This is why a method validated in solvent is not automatically validated in kratom powder. It is also why leaf powder, pure-leaf capsules and concentrated liquids should not be treated as one interchangeable matrix.

Matrix-matched calibration, internal standards, standard additions, recovery experiments, cleanup procedures and appropriate dilutions are among the tools laboratories may use. The right approach depends on the method.

Reference standards, reference materials and metrological traceability

Results ultimately depend on what the laboratory uses as a reference.

A useful review distinguishes:

• Reference standard: a material used to establish identity, calibration or response;
• Reference material: material sufficiently homogeneous and stable for a specified use;
• Certified reference material: a reference material supplied with documented property values, uncertainties and traceability under its certificate; and
• Internal standard: a compound added in a known way to help correct or monitor aspects of preparation or instrument response.

The certificate should identify which value is assigned, how it was characterized, the uncertainty, storage conditions, expiration or retest information and any limitations. Purity or potency corrections may be needed when preparing calibration solutions.

Traceability does not mean that a result is perfect. It means the result can be related to an appropriate reference through a documented chain of calibrations or comparisons, each contributing uncertainty.

When no ideal matrix-matched certified material exists, the laboratory should document the alternative evidence and limitations instead of implying that the reference problem disappeared.

Validation does not replace batch quality control

Validation shows expected method capability. Routine controls help show whether the process remained under control when a particular sample was tested.

Depending on the method, an analytical batch may include:

• reagent or method blanks;
• calibration standards;
• continuing calibration checks;
• reference materials;
• laboratory control samples;
• fortified or spiked samples;
• matrix duplicates;
• sample duplicates;
• internal-standard acceptance checks;
• positive and negative controls;
• system-suitability samples; and
• control-chart review.

FDA’s Elemental Analysis Manual includes method-specific quality-control requirements and explains that a failed QC element can require reanalysis of affected results. The exact response depends on what failed and which analytes or samples may be affected.

A customer COA usually does not list every QC result. That is normal. The laboratory should retain the complete batch record, predefined acceptance criteria, investigation and corrective-action documentation. The public report should not imply that the mere presence of a number proves the batch controls passed.

Measurement uncertainty: the honest space around a result

Every quantitative measurement is an estimate. Measurement uncertainty characterizes the dispersion of values reasonably attributable to the quantity being measured.

Possible components include:

• balance calibration and repeatability;
• volumetric operations;
• reference-standard value and preparation;
• calibration-model variation;
• recovery and matrix effects;
• intermediate precision;
• sample preparation;
• moisture-basis conversion; and
• other method-specific contributors.

Uncertainty is not the same as an error or mistake. Reporting uncertainty does not mean the laboratory lacks confidence; it means the result is being described with appropriate metrological context.

A laboratory may report a standard uncertainty, combined standard uncertainty or expanded uncertainty. An expanded uncertainty is often presented with a coverage factor, but the meaning and confidence interpretation should be stated rather than assumed.

NIST’s measurement-uncertainty resources emphasize defining the measurement process, identifying and quantifying components, combining them and reporting the result appropriately. The calculation must match the measurand and routine method.

Why uncertainty matters near a limit

Imagine a specification of “not more than 1.00” in the same units as a result. A report of 0.99 and expanded uncertainty of 0.08 does not have the same decision context as 0.99 with uncertainty of 0.01. Whether the lot is accepted depends on the specification wording and the agreed decision rule.

A decision rule explains how measurement uncertainty is considered when stating conformity. Possible approaches can create guard bands or place different risks on false acceptance and false rejection. Website staff should not invent a decision rule after seeing a borderline result.

Near a threshold, reviewers should ask:

1. What exactly is the legal or internal limit?
2. Is the result on the correct product-weight, dry-weight, serving, article or alkaloid-fraction basis?
3. Was the result inside the validated range?
4. What rounding was applied?
5. Is uncertainty reported or available?
6. What decision rule governs the conformity statement?
7. Does the report actually state pass/fail, or is a seller adding that claim?

Method changes can trigger new validation work

Methods evolve. A different column, extraction solvent, instrument model, software integration rule, analyte list, matrix, calibration range or sample amount may affect performance.

Not every minor change requires a complete validation from zero. The laboratory should use a controlled change process that:

• describes the proposed change;
• assesses possible impact;
• identifies the validation or verification experiments needed;
• defines acceptance criteria;
• records results and approval; and
• updates the controlled procedure and training.

FDA’s Office of Regulatory Affairs Laboratory Manual distinguishes method verification, validation and modification and instructs laboratories to assess the extent and impact of changes. A report that says only “modified method” provides little customer context. The laboratory should be able to explain the modification and the supporting evidence.

Chemistry and microbiology validation are not identical

Chemical methods often produce a continuous numerical result. Microbiological methods may produce qualitative detection, counts, organism identification or another type of result. Their validation designs differ.

For a pathogen method, relevant characteristics can include inclusivity, exclusivity, matrix effects, probability of detection, relative performance, confirmation and robustness. For a plate-count method, counting range, dilution, precision and recovery may be important.

Do not apply a chemistry-only checklist mechanically to Salmonella, yeast and mold or bacterial-count testing. FDA publishes separate Foods Program guidelines for chemical, microbiological and DNA-based methods for this reason.

What a kratom alkaloid method should make clear

For a customer or buyer reviewing mitragynine or 7-OH results, the report or supporting laboratory information should make it possible to determine:

• which alkaloids are included;
• whether they are adequately separated and identified;
• the sample matrix;
• the extraction and instrument method reference;
• the units and calculation basis;
• the quantitative range;
• LOD, LOQ or reporting limit where relevant;
• whether high samples were diluted;
• whether the result is as-received or dry-weight;
• which results are within the accredited scope;
• whether the sample and package lots match; and
• how borderline conformity decisions are made.

An “alkaloid panel” is not a standardized universal panel. Two laboratories may include different targets, use different standards, report different units or apply different confirmation criteria.

Current federal 7-OH context makes fit-for-purpose testing especially important

As reviewed on August 29, 2026, HHS has an open request-for-information process concerning a proposed federal 7-OH threshold. The proposal discusses 0.050% by weight and 1 milligram per article, but those criteria are proposals—not an effective federal scheduling threshold. HHS extended the public-comment deadline to September 10, 2026.

A separate DEA order is already effective: mitragynine pseudoindoxyl, MGM-15 and MGM-16 are temporarily in Schedule I from August 26, 2026 through August 26, 2028, unless extended or made permanent through further action.

Those two federal actions must remain separate in Kiody content. Ordinary botanical leaf should not be described as federally banned by the pending 7-OH threshold action. Kiody does not sell concentrated 7-OH.

From a laboratory perspective, any low threshold increases the importance of:

• correct units and denominator;
• method selectivity;
• an LOQ suitable for the threshold;
• reference-standard identity and purity;
• validated matrix and range;
• dilution and dry-weight calculations;
• rounding and uncertainty; and
• a predefined decision rule.

A website should not convert a COA screenshot into a legal conclusion without qualified laboratory and legal review.

Product form changes the testing question

Botanical leaf powder

The method should be suitable for dried, milled botanical material and its expected analyte range. Representative sampling and homogenization are critical because the laboratory analyzes only a portion.

Pure-leaf capsules

Kiody describes its capsules as pure botanical leaf with approximately 500 mg fill per capsule where verified. A powder method may be usable for the fill material, but finished-capsule review should confirm sample preparation, capsule-shell handling, lot identity and the unit or basis being reported.

Extracts and enhanced products

Higher analyte concentrations, different carriers and more complex formulations may require different dilution, cleanup and matrix evidence. A method validated for botanical leaf should not be assumed to cover every extract.

Concentrated or synthetic 7-OH products

These are not equivalent to ordinary botanical leaf. Kiody does not sell concentrated 7-OH. Educational references to such products should not be used as marketing language or imply medical benefits, safety or legal availability.

A proposed Kiody laboratory-method record

For each test used to support a product-quality claim, Kiody could maintain a controlled record with:

1. laboratory legal name and testing location;
2. accreditation body, number and current scope entry;
3. method identifier, title and revision;
4. analyte or organism list;
5. approved product matrices;
6. intended use and specification supported;
7. validated or verified range;
8. LOD, LOQ and reporting-limit conventions;
9. units and calculation basis;
10. reference standards or materials;
11. summary of selectivity, accuracy/recovery and precision evidence;
12. uncertainty availability and decision rule;
13. routine batch-QC elements;
14. sample amount and handling requirements;
15. subcontracted steps or laboratories;
16. report-authentication process;
17. latest method or scope review date;
18. method-change notification requirement;
19. deviations or limitations relevant to Kiody products; and
20. quality-unit approval and next review date.

This is a proposed internal quality record, not a statement that Kiody currently maintains every field or that any listed method is FDA-approved.

A 60-second customer checklist

When looking at a kratom COA, ask:

• Does the product and lot match the package?
• Is the sample described as leaf, powder, capsule, extract or another matrix?
• Is the method named?
• Are result units shown?
• Is the weight or calculation basis clear?
• Are LOD, LOQ or reporting limits available for low-level results?
• Is the laboratory and testing location identifiable?
• Does the current accreditation scope cover the method and matrix?
• Are amended or superseded reports clearly controlled?
• Does the company avoid turning “tested” into “safe,” “approved” or “zero risk”?

If several answers are missing, request the complete report and clarification. Missing information is not automatic proof of fraud, but it is a reason not to overinterpret the result.

Common warning signs

• “Validated method” with no method identifier, matrix or intended range
• A report for leaf powder attached to a concentrated liquid product
• A 7-OH result below a legal threshold when the LOQ is above that threshold
• “ND” rewritten as “zero” or “free from”
• Calibration performed with an unidentified or expired standard
• Only repeated injections, presented as complete method precision
• Recovery tested after extraction, then claimed to validate extraction efficiency
• No separation or confirmation evidence for related alkaloids
• Results outside the calibration range with no supported dilution
• A pass/fail statement with no specification or decision rule
• An ISO/IEC 17025 logo used as if every result is accredited
• A vendor saying “FDA-certified kratom laboratory” without a precise, verifiable federal program

Frequently asked questions

1. Does “validated method” mean the result is guaranteed correct?

No. Validation provides evidence that a method can perform adequately for a defined use. Sampling, execution, calculations, quality control, report accuracy and lot matching still matter.

2. Is a published method automatically valid in every laboratory?

No. The laboratory should verify that it can perform the method appropriately, and it must evaluate whether the method covers the intended matrix, analytes, range and purpose.

3. Is an ISO/IEC 17025-accredited laboratory enough?

Accreditation is important evidence of competence, but scope is specific. Confirm the location, method, analyte and matrix, and determine whether the particular result is within the accredited scope.

4. What is the difference between accuracy and precision?

Precision describes agreement among repeated results. Accuracy or trueness concerns agreement with an accepted reference or assigned value. Results can be precise but consistently biased.

5. Why are replicate injections not enough?

They mainly evaluate instrument and injection repeatability for one prepared solution. They may not capture weighing, extraction, dilution, analyst, day or sample-portion variation.

6. Does “not detected” mean none is present?

No. It means the method did not detect the analyte under its reporting convention. The detection or reporting limit is needed to understand the statement.

7. Can a method report below its LOQ?

A method may detect or estimate a signal below the LOQ, but it should not present that estimate as having the same quantitative reliability as a result inside the validated range. The laboratory’s convention should be clear.

8. What is a matrix effect?

It is an effect from other components of the sample that changes extraction, separation or detector response. Botanical leaf, capsules and extracts can behave differently.

9. What is a certified reference material?

It is a reference material accompanied by documentation assigning specified property values, uncertainties and traceability. Its certificate and intended use must match the measurement question.

10. Why does measurement uncertainty matter to customers?

It provides context for how much dispersion is reasonably associated with a numerical result. It is especially important when a result is near a specification or legal threshold.

11. Can the same method test leaf and concentrated extracts?

Possibly, but not automatically. The laboratory needs evidence for each matrix and concentration range, including preparation, dilution, matrix effects and recovery.

12. Does a passing COA prove a product is safe?

No. It reports results for the submitted sample and named tests. It does not evaluate every possible contaminant, every package, every use, individual response or changing legal status.

13. Is the proposed federal 7-OH threshold already law?

No. As of August 29, 2026, the 0.050%-by-weight and 1-milligram-per-article criteria remain proposals in an HHS comment process ending September 10, 2026. The separate DEA order for mitragynine pseudoindoxyl, MGM-15 and MGM-16 is effective.

Source notes and citations

Authoritative government and standards sources

1. U.S. Food and Drug Administration, Foods Program Methods Validation Processes and Guidelines, reviewed December 11, 2023. Describes FDA’s method-development, validation and implementation framework and links separate chemical, microbiological and DNA-method guidelines.
2. U.S. Food and Drug Administration, Guidelines for the Validation of Chemical Methods for the FDA Foods Program, third edition, 2019. Defines validation levels and common performance characteristics for chemical regulatory methods in foods, feeds and cosmetics.
3. Electronic Code of Federal Regulations, 21 CFR § 111.320, current through August 29, 2026. Used as a quality-system benchmark for intended-use verification and scientifically valid methods, not as a kratom approval statement.
4. U.S. Food and Drug Administration, ORA Laboratory Manual, Volume II: Methods, Method Verification and Validation, revision 3, October 31, 2023. Controlled method verification, validation, modification and change-assessment concepts.
5. U.S. Food and Drug Administration, Elemental Analysis Manual, updated March 6, 2026. FDA elemental methods, reference materials, validation and batch quality-control examples.
6. U.S. Food and Drug Administration, EAM Section 3.5: Reference Materials, December 2021. Reference-material use in validation, verification, calibration and quality control.
7. National Institute of Standards and Technology, Quantifying Measurement Uncertainty in Analytical Measurement. Analytical-chemistry uncertainty concepts and examples.
8. National Institute of Standards and Technology, SOP 29: Assignment of Uncertainty, 2019. Eight-step uncertainty-evaluation framework.
9. International Organization for Standardization, ISO/IEC 17025 overview. General testing- and calibration-laboratory competence standard overview.

Kratom-specific primary analytical research

10. Sharma A, et al., Simultaneous quantification of ten key kratom alkaloids in Mitragyna speciosa leaf extracts and commercial products by UPLC-MS/MS, 2019. Primary method-development and validation study covering accuracy, precision, robustness and stability.
11. Manwill PK, et al., Kratom (Mitragyna speciosa) Validation: Quantitative Analysis of Indole and Oxindole Alkaloids Reveals Chemotypes of Plants and Products, 2022. Primary UPLC-HRMS method and complex-alkaloid analysis.
12. Sheehan D, et al., Avoiding False Identification of 7-Hydroxymitragynine in Commercial-Product Analysis, 2026. Primary research on selectivity and reliable identification of relevant kratom alkaloids.

Current federal regulatory sources

13. Department of Health and Human Services, 7-OH threshold comment-period extension, August 26, 2026. Extends comments through September 10, 2026; does not itself create an effective threshold.
14. Drug Enforcement Administration, Proposed temporary placement of 7-OH above a specified threshold, July 6, 2026. Proposed 0.050%-by-weight and 1-milligram-per-article criteria.
15. Drug Enforcement Administration, Temporary Schedule I placement of mitragynine pseudoindoxyl, MGM-15 and MGM-16, effective August 26, 2026 through August 26, 2028.
16. U.S. Food and Drug Administration, FDA and Kratom, updated December 2, 2025. Current FDA status and no-approved-drug context.